Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2022-11-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司关于全资子公司药品临床试验申请取得受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its wholly-owned subsidiary receiving an acceptance notice for a clinical trial application from the National Medical Products Administration (NMPA) in China. It details the drug information, development status, and risk warnings. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no earnings release, and no regulatory certifications. The document is a regulatory announcement about a clinical trial acceptance, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-11-22 Chinese
中源协和细胞基因工程股份有限公司被冻结银行账户信息情况公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the freezing of the company's bank accounts due to litigation. It provides details about the frozen accounts, the amounts involved, and the impact on the company's operations. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a legal and financial situation affecting the company, but it is not a full legal proceedings report or audit report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-11-18 Chinese
中源协和细胞基因工程股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report." It is issued by 中源协和细胞基因工程股份有限公司 and involves 富策产业投资（天津）有限公司 and its related parties. The content extensively details the equity ownership changes, control relationships, shareholding structures, and related disclosures. It references compliance with Chinese securities laws and regulations specifically related to equity changes and disclosures. The document is lengthy (15,000 characters) and contains detailed information about shareholding changes, control, and related parties, which aligns with a Major Shareholding Notification. There is no indication that this is an announcement of a report publication or a certification letter, nor is it a full annual or interim financial report. The focus is on equity changes and disclosures of significant share ownership, consistent with the category "Major Shareholding Notification (MRQ)."
2022-11-08 Chinese
东方证券承销保荐有限公司关于中源协和细胞基因工程股份有限公司详式权益变动报告书之财务顾问核查意见
Major Shareholding Notification Classification · 95% confidence The document is titled as a "详式权益变动报告书之财务顾问核查意见" which translates to "Detailed Equity Change Report - Financial Advisor's Verification Opinion." It references compliance with Chinese securities laws and regulations, including the "上市公司收购管理办法" (Measures for the Administration of Takeovers of Listed Companies) and disclosure standards for equity change reports. The content includes detailed verification of the equity change report, information about the parties involved, their shareholdings, and related corporate structures. This is a detailed report related to a significant equity change (ownership change) in a listed company, with financial advisor verification. It is not an announcement of voting results, not a general regulatory filing, nor a simple announcement. It is a formal, detailed equity change report with financial advisor's audit and verification opinions. Therefore, the document fits the category of "Major Shareholding Notification" (MRQ), which covers notifications of changes in significant share ownership levels and related detailed reports.
2022-11-08 Chinese
中源协和细胞基因工程股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details the change in shareholding by an information disclosure obligor (天津红磡投资发展股份有限公司) in the listed company 中源协和细胞基因工程股份有限公司. The document includes sections on the purpose of the equity change, the method of equity change (agreement transfer and indirect transfer), details of shareholding before and after the change, and related agreements. It also references compliance with Chinese securities laws and regulations regarding equity changes. The document is a formal report on changes in significant share ownership levels, consistent with the definition of a Major Shareholding Notification (MRQ). It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result announcement. Therefore, the correct classification is Major Shareholding Notification (MRQ). The document length (over 10,000 characters) and detailed content support a high confidence in this classification.
2022-11-08 Chinese
中源协和细胞基因工程股份有限公司关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding changes in shareholder equity structure, specifically the transfer of shares within a shareholder company (Tianjin Deyuan Health Management Co., Ltd.) without changes to the controlling shareholder or actual controller of the listed company (Zhongyuan Xiehe Cell Gene Engineering Co., Ltd.). It includes detailed information about the parties involved, shareholding percentages before and after the transfer, and the terms of the share transfer agreements. The document does not contain financial statements, audit results, or earnings data. It is not a report of voting results, nor is it a proxy solicitation or remuneration report. It is a regulatory announcement about a change in major shareholding structure but does not indicate a change in control or a takeover bid. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds or notable share transfers. The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of shareholding changes.
2022-11-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.